All News
Postural Orthostatic Tachycardia Syndrome Review
The Cleveland Clinic Journal has published a full-read review of postural orthostatic tachycardia syndrome (POTS), a condition often seen in clinic with symptoms like fibromyalgia, but is clinically diagnosed with finding sustained tachycardia upon standing without orthostatic hypotension.
Read Article
Targeted therapies in Sjogren’s syndrome: are we close?
There is a clear unmet need for new and effective therapies in primary Sjogren’s Syndrome (pSS) patients, as there are no current licensed therapies.
#ACR23 Abstr#2335 A step towards equal access to therapy for ANA+ people with arthritis. A cohort study showed: ANA+ (#SLE, #sjogren, MCTD, UCTD) & arthritis were homogenous related to clinical features, PROs & gene expression score. Offer rationale for basket trial @RheumNow https://t.co/7HTMxE7mSP
Md Yuzaiful Md Yusof ( View Tweet)
#ACR23 Abstr#1636 Phase 2 crossover RCT of Dazodalibep, Anti-CD40L-i in #Sjogren pts with high disease activity showed primary endpoint, change in ESSDAI was met in DAZ vs PBO. More COVID in DAZ in Stage 1 but trial was at the start of pandemic. Phase 3 is starting soon @RheumNow https://t.co/hZcpOHumB3
Md Yuzaiful Md Yusof ( View Tweet)
#ACR23 Abstr#1634 Promising therapy for two #Sjogren groups: 1 (high ESSDAI & ESSPRI) & 2 (low ESSDAI, high ESSPRI). Phase 2 RCT of Iscalimab (anti-CD40ab) showed more ISC-treated pts met the primary endpoint (ESSDAI and ESSPRI changes at WK24) vs PBO. Going to Phase 3 @RheumNow https://t.co/3bN3IS1zCO
Md Yuzaiful Md Yusof ( View Tweet)
#ACR23 Abstr#0509 Is sero-ve #Sjogren sero-ve? A study showed promising diagnostic model comprises clinical & novel autoantibodies (DTD2) using whole peptidome array (AUC:74%) to avoid need for lips biopsy in ANA-ve. Need further validation & wider access to this test @RheumNow https://t.co/FmE8AJdMVe
Md Yuzaiful Md Yusof ( View Tweet)
You should not tire of hearing this! Phase2 RCT of #dazodalibep -CD40L antagonist for #extra glandular & could also have #glandular problems in #Sjogrens was + improving Facit #fatigue & ESSPRI, etc. #GameChanger #ACR23 #ACRbest @ACRheum @RheumNow Pos#L10 https://t.co/DfChrAyslL
Janet Pope ( View Tweet)
#ACR23 Abstr#PP12 "I am stronger than my disease & won’t let it stop me from leading a fulfilling life!"- a person with #Sjogren shared tips on lifestyle modification to help fatigue.
- schedule appointments in the morning
- exercise
- keep a diary
- listen to body
@RheumNow https://t.co/8ROFrDvPS1
Md Yuzaiful Md Yusof ( View Tweet)
Full read review of clinical trials in CTD-ILD, specifically looking at:
- Frequency of ILD in RA, SLE, SSc, Sjogr, PM/DM & Rx outcomes
- Results w/ RTX, MMF, CYC, IL-6i, nintedinib, pirfenidone, Stem cell transplant
https://t.co/HyCsrzejLU https://t.co/ejJKOtXupC
Links:
Dr. John Cush RheumNow ( View Tweet)
Full read review of clinical trials in CTD-ILD, specifically looking at:
- Frequency of ILD in RA, SLE, SSc, Sjogr, PM/DM & Rx outcomes
- Results w/ RTX, MMF, CYC, IL-6i, nintedinib, pirfenidone, Stem cell transplant
https://t.co/gUOV3IWt4P https://t.co/WM1HvTmNCq
Links:
Dr. John Cush RheumNow ( View Tweet)
RT @Yuz6Yusof : #EULAR2023 #OP0143 Promising therapy. A Phase 2 RCT of Dazodalidep (CD40L-i) in #Sjogren showed significantly more patients on DAZ group met reduction in ESSDAI vs placebo. Interesting to see higher hurdle ESSDAI favored DAZ Group. Phase 3 RCTs are underway
Dr. John Cush RheumNow ( View Tweet)
RT @drdavidliew : Dazodalibep is the next CD40L inhibitor being tested in Sjogren’s - we need better therapies reducing symptom burden. Nice phase 2 data analyses so far of subjective measures, and plenty will be happy if we see this kind of result in phase 3
LB0003 #EULAR2023
Dr. John Cush RheumNow ( View Tweet)
Dazodalibep: A Glimmer of Hope is Sjogren's Syndrome?
Dr. Yuz Yusof reports on abstracts OP0143 and LB0003 presented at EULAR 2023 in Milan, Italy.
https://t.co/TPcdJ2rIsP https://t.co/5WZizA0TU8
Links:
Dr. John Cush RheumNow ( View Tweet)
Targeted therapies in Sjogren’s syndrome: are we close?
There is a clear unmet need for new and effective therapies in primary Sjogren’s Syndrome (pSS) patients, as there is no current licensed therapies.
https://t.co/B4kKDjhuh7 https://t.co/pGWpSNhJe2
Links:
Dr. John Cush RheumNow ( View Tweet)
#Sjogrens has a positive RCT with Dazodalibep. Well tolerated in Phase 2 RCT - Congratulations -heading to phase 3 Primary outcome positive but not 2ndary but not powered for them @RheumNow #EULAR2023 @eular_org LB0003 #SSj https://t.co/Qt0KTaNjsR
Janet Pope Janetbirdope ( View Tweet)
#EULAR2023 #LB0003 It is unheard of therapies that potentially can improve Sjogren patients with high symptoms burden. Phase 2 RCT of Dazodalibep (CD40L-i) showed ESSPRI improved vs PBO. Numerical improvement in other secondary (Fatigue). Will await results in Phase 3 @RheumNow https://t.co/0NzR83apeY
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Dazodalibep is the next CD40L inhibitor being tested in Sjogren’s - we need better therapies genuinely reducing symptom burden. Nice phase 2 data analyses so far of subjective measures, and plenty will be happy if we see this kind of result in phase 3
LB0003 #EULAR2023 @RheumNow https://t.co/HYcXEzswAg
David Liew drdavidliew ( View Tweet)
#Deeplearning in salivary biopsies in #SjogrensSyndrome - 327 pts - binary focus score (>=1) prediction the AUROC was 0.87 and for primary sjogrens diagnosis prediction it was 0.84
Quicker and cost effective in the future?
@rheumnow #EULAR2023 abst#OP0232 https://t.co/Ec0zuKqpXf
Bella Mehta bella_mehta ( View Tweet)
Could mitochondria play a role in the pathogenesis of Sjogrens disease?!
#Eular2023 https://t.co/XndW4qFf3E
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Malt lymphoma in Sjogrens disease and role of PET scan.
When is PET scan suggestive?
Follow:
Complement
RF
Focus score
SPEP
#Eular2023 https://t.co/60l8iRNvQN
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
